Subchronic Administration and Combination Metabotropic Glutamate and GABA<sub>B</sub> Receptor Drug Therapy in Fragile X Syndrome

Laura K. K. Pacey, Sujenthar Tharmalingam, and David R. Hampson

Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy (L.K.K.P, S.T., D.R.H.), and Department of Pharmacology, Faculty of Medicine (D.R.H.), University of Toronto, Toronto, Ontario, Canada

Received April 25, 2011; accepted May 31, 2011

ABSTRACT

The most common cause of inherited mental retardation, fragile X syndrome, results from a triplet repeat expansion in the FMR1 gene and loss of the mRNA binding protein, fragile X mental retardation protein (FMRP). In the absence of FMRP, signaling through group I metabotropic glutamate receptors (mGlRs) is enhanced. We previously proposed a mechanism whereby the audiogenic seizures exhibited by FMR1 null mice result from an imbalance in excitatory mGlR and inhibitory GABA<sub>B</sub> receptor (GABA<sub>B</sub>R) signaling (Mol Pharmacol 76:18–24, 2009). Here, we tested the mGlR5-positive allosteric modulator 3-cyano-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide (CDPPB), the mGlR5 inverse agonist 2-methyl-6-(phenylethynyl)pyridine (MPEP), and GABA<sub>B</sub> receptor agonists, alone and in combination on receptor protein expression and audiogenic seizures in FMR1 mice. Single doses of MPEP (30 mg/kg), the GABA<sub>B</sub>R orthosteric agonist R-baclofen (1 mg/kg), or the GABA<sub>B</sub>R-positive allosteric modulator N,N′-dicyclopentyl-2-(methylthio)-5-nitro-4,6-pyrimidine diamine (GS-39783) (30 mg/kg), reduced the incidence of seizures. However, when administered subchronically (daily injections for 6 days), MPEP retained its anticonvulsant activity, whereas R-baclofen and GS-39783 did not. When administered at lower doses that had no effect when given alone, a single injection of MPEP plus R-baclofen also reduced seizures, but the effect was lost after subchronic administration. We were surprised to find that subchronic treatment with R-baclofen also induced tolerance to a single high dose of MPEP. These data demonstrate that tolerance develops rapidly to the antiseizure properties of R-baclofen alone and R-baclofen coadministered with MPEP, but not with MPEP alone. Our findings suggest that cross-talk between the G-protein signaling pathways of these receptors affects drug efficacy after repeated treatment.

Introduction

Fragile X syndrome (FXS) is caused by the expansion of a CGG triplet repeat in the 5′ untranslated region of the FMR1 gene, which induces silencing of gene expression and the absence of the mRNA-binding protein fragile X mental retardation protein (FMRP). The “mGlR Theory of Fragile X” (Bear et al., 2004) postulates that, in the absence of FMRP, protein translation downstream of group I metabotropic glutamate receptors (mGlRs) is abnormal, leading to enhanced mGlR signaling, which contributes to many of the phenotypes associated with FXS. The mGlR theory also suggests that reducing group I mGlR (mGlR1 and mGlR5) signaling should alleviate some of the symptoms of FXS (Bear, 2005). Indeed, treatment with mGlR5 antagonists has been shown to reduce seizures and hyperactivity in FMR1 KO mice (Yan et al., 2005), restore dendritic spine defects in cultured neurons lacking FMRP (de Vrij et al., 2008), and correct behavioral deficits in FMR1 null flies (McBride et al., 2005). Genetic reduction of mGlR5 expression in mice also rescues several FXS phenotypes including abnormal ocular dominance plasticity, increased protein synthesis, seizures, and spine defects (Dölen et al., 2007).

ABBREVIATIONS: FXS, fragile X syndrome; CDPPB, 3-cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide; FMRP, fragile X mental retardation protein; mGlR, metabotropic glutamate receptor; MPEP, 2-methyl-6-(phenylethynyl)pyridine; PND, postnatal day; GS-39783, N,N′-dicyclopentyl-2-(methylthio)-5-nitro-4,6-pyrimidine diamine; GABA<sub>B</sub>R, GABA<sub>B</sub> receptor; CGP46381, (3-aminopropyl)(cyclohexylmethyl)phosphinic acid; DMSO, dimethyl sulfoxide; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; KO, knockout; WT, wild type; PEG, polyethylene glycol; MTEP, 3-[2-methyl-1,3-thiazol-4-yl]ethenyl]pyridine.
Although much focus has been placed on group I mGluRs, evidence for changes in the GABAergic system in FXS has emerged, and both group I mGluR antagonists and GABA<sub>B</sub> receptor agonists are being tested in clinical trials of FXS (see Hampson et al., 2011 for a review). GABA exerts its effects through two distinct families of receptors. The ionotropic GABA<sub>A</sub> receptors are pentameric chloride channels that mediate fast inhibition through controlling the movement of chloride across the cell membrane, whereas metabotropic GABA<sub>B</sub> receptors are heteromeric G protein-coupled receptors that require dimerization of the R1 and R2 subunits to form fully functional receptors. GABAB receptors are receptors that require dimerization of the R1 and R2 subunits. GABAB receptors are localized presynaptically or postsynaptically where they mediate slow inhibition through G<sub>ai</sub>-mediated inhibition of adenylyl cyclase and/or activation of inwardly rectifying K<sup>+</sup> channels. Presynaptic GABA<sub>B</sub> receptors also regulate the release of glutamate (Vigot et al., 2006).

Decreased GABA<sub>B</sub> receptor expression and function has been demonstrated in FMR1 knockout mice (El Idrissi et al., 2005; D’Hulst et al., 2006, 2009; Curia et al., 2009; Adusei et al., 2010; Olmos-Serrano et al., 2010). We have also recently demonstrated that GABA<sub>B</sub>R1 expression is down-regulated in the forebrains of immature and mature FMR1 mice compared with wild-type mice (Pacey et al., 2011). This observation is particularly interesting because GABA<sub>B</sub> receptor expression has also been reported to be reduced in the brains of persons with autism, a disorder related to FXS. 

The purpose of the present study was 3-fold. The first goal was to investigate the effectiveness of a combination of (2-aminopropyl)(cyclohexylmethyl)phosphinic acid (CGP46381; Tocris Bioscience) in 20% β-cyclodextrin (Sigma-Aldrich, St. Louis, MO); GS-39783 (Tocris Bioscience) suspended in 10% polyethylene glycol (PEG) 200/15% DMSO/75% sterile saline; and CDPPB (Tocris Bioscience) suspended in 50% DMSO/50% sterile saline.

Western Blotting. Immediately after seizure testing, mice were euthanized with an overdose of ketamine/xylazine, and the brains were removed and frozen on dry ice. Quantitative Western blotting was performed on whole forebrain homogenates as described previously (Adusei et al., 2010). The following antibodies were used: mouse anti-GABA<sub>B</sub>R1 (clone NR3A/49; 1:250; NeuroMab, University of California, Davis, CA/National Institutes of Health); rabbit anti-GABABR2 (clone N81/2; 1:750; NeuroMab, University of California, Davis/National Institutes of Health); mouse anti-GABABR1 (clone NR3A/49; 1:250; NeuroMab, University of California, Davis/National Institutes of Health, Bethesda, MD); mouse anti-GABA<sub>B</sub>R2 (clone N81/2; 1:750; NeuroMab, University of California, Davis/National Institutes of Health); rabbit anti-mGluR5 (1:500; Millipore Bioscience Research Reagents, Temecula, CA); mouse anti-GAPDH antibody (1:40,000–1:100,000; Sigma-Aldrich); and a goat anti-mouse (The Jackson Laboratory, Bar Harbor, ME) or goat anti-rabbit (Thermo Fisher Scientific, Waltham, MA) horseradish peroxidase-conjugated secondary antibody. The immunoreactive proteins were visualized using the FluorChem Multimage Light Cabinet (Alpha Innotech, San Leandro, CA). Densitometric analysis was carried out using AlphaEaseFC software (Alpha Innotech). The intensity of the band of interest was normalized relative to the GAPDH band intensity. Protein expression in drug-treated animals is presented as a percentage of expression in vehicle controls. An unpaired Student’s t test was used to determine statistical significance.

Results

Acute Administration of MPEP, R-Baclofen, or GS-39783 Reduced Seizures in FMR1 Mice. FMR1 knockout mice are susceptible to audiogenic seizures (Chen and Toth, 2001). Because the incidence of audiogenic seizures is very low (~5%) in wild-type C57BL/6 mice (Pacey et al., 2009), only FMR1 knockout mice were used in this study. Single
injections of MPEP (Yan et al., 2005) and R-baclofen (Pacey et al., 2009) have been previously shown to reduce the incidence of audiogenic seizures in FMR1 mice. To confirm these results, FMR1 mice were treated with 30 mg/kg MPEP or 1 mg/kg R-baclofen 60 min before seizure testing (Fig. 1A). Vehicle-treated FMR1 mice had a seizure incidence of 60%. Both 30 mg/kg MPEP and 1 mg/kg R-baclofen significantly reduced seizure incidence to 13% (p = 0.03 compared with vehicle). The GABAB receptor-positive allosteric modulator GS-39783 was also tested for its antiseizure capabilities. GS-39783 (30 mg/kg) reduced seizures in FMR1 mice to 25% compared with vehicle controls (10% PEG/15% DMSO/75% saline), which had a seizure rate of 69%, although this difference did not quite reach statistical significance (p = 0.054; Fig. 1A).

**FMR1 Mice Develop Tolerance to R-Baclofen and GS-39783 but Not MPEP after Repeated Administration.** Next, we determined whether these drugs could maintain their anticonvulsant activities after subchronic administration. FMR1 mice were injected with MPEP (30 mg/kg), R-baclofen (1 mg/kg), GS39783 (30 mg/kg), or vehicle daily for 6 days beginning on PND25. Seizure testing was carried out 60 min after the final injection on PND30. After subchronic administration, 82% of vehicle-treated mice had seizures (note that the seizure incidence in the vehicle group was consistently higher after subchronic administration compared with a single injection), whereas none of the eight animals treated with 30 mg/kg MPEP had seizures (p = 0.0007; Fig. 1B). This indicated that MPEP retained its anticonvulsant activity after subchronic administration. In contrast, the anticonvulsant efficacy of R-baclofen and GS-39783 was reduced after subchronic administration compared with single drug injections (Fig. 1B), with 50 and 38% of animals exhibiting seizures, respectively, compared with controls after six daily injections (p = 0.32 and 0.18, respectively, compared with vehicle).

**Acute Administration of a Combination of Low-Dose MPEP and R-Baclofen Prevents Seizures in FMR1 KO Mice.** Given that targeting mGluR5 or GABAB receptors alone can alleviate seizures in FMR1 mice, we postulated that treating mice with combined low doses of MPEP and R-baclofen should also reduce seizures and using low doses of both drugs might prevent the tolerance seen with the high dose of R-baclofen. Treatment with 10 mg/kg MPEP alone or 0.5 mg/kg R-baclofen alone did not significantly affect the incidence of audiogenic seizures compared with vehicle controls (67% seizures for MPEP or R-baclofen alone; 60% seizures for vehicle; Fig. 2A). However, when animals were treated simultaneously with a combined dose of 10 mg/kg MPEP plus 0.5 mg/kg R-baclofen the incidence of seizures dropped to 17% (p = 0.03 compared with vehicle). This finding demonstrates that low doses of MPEP and R-baclofen that are not anticonvulsant when administered alone can significantly reduce seizure activity when administered in combination. This finding supports the theory that an imbalance in mGluR and GABAB receptor signaling contributes to audiogenic seizures in FMR1 null mice.

**FMR1 Mice Develop Tolerance to Combined Low-Dose MPEP Plus R-Baclofen after Repeated Administration.** We also tested whether the combination of 10 mg/kg MPEP plus 0.5 mg/kg R-baclofen maintained its anticonvulsant activity after repeated administrations (Fig. 2B). Similar to a single injection, six daily injections of either 10 mg/kg MPEP or 0.5 mg/kg R-baclofen alone did not affect seizure incidence with 89 and 78% of animals exhibiting seizures, respectively, compared with 88% of vehicle controls (p = 1.0 and 1.0, respectively). We were surprised to find that the combination of 10 mg/kg MPEP plus 0.5 mg/kg R-baclofen no longer prevented seizures after repeated injections, with 78% of animals exhibiting seizures (p = 1.0).

**mGluR5 and GABAB Receptor Expression after Repeated Administration of MPEP, R-Baclofen, and GS-39783.** mGluR5 and GABAB receptor subunit expression was examined in the forebrains of mice treated subchronically with 30 mg/kg MPEP, 1 mg/kg R-baclofen, or 30 mg/kg GS-39783. Western blot analysis indicated that there was no difference in mGluR5 expression in the brains of FMR1 mice treated subchronically with 30 mg/kg MPEP compared with vehicle controls (103.4 ± 7.0% of vehicle; p > 0.05; Fig. 3, E and F). Subchronic treatment with R-baclofen induced a small, nonsignificant decrease in GABABR1 (80.4 ± 4.7% of vehicle; p > 0.05) and GABABR2 (90.2 ± 5.6%; p > 0.05; Fig. 3, C and D) compared with vehicle controls. It is noteworthy that mice treated with GS-39783 displayed a dramatic reduc-

---

**Fig. 1.** The effects of single and repeated doses of MPEP, R-baclofen, and GS-39783 on audiogenic seizures in FMR1 mice. A, when administered as single doses 60 min before testing MPEP (30 mg/kg) and R-baclofen (1 mg/kg) significantly reduced seizure susceptibility in FMR1 mice. The GABAB receptor-positive allosteric modulator GS-39783 produced a non-significant reduction in seizure incidence. B, FMR1 mice were injected with vehicle, MPEP, R-baclofen, or GS-39783 daily for 6 days starting on PND25 and tested for audiogenic seizures 60 min after the final injection on PND30. After subchronic treatment, MPEP retained anticonvulsant activity, whereas R-baclofen and GS-39783 did not.
There was no significant difference in GABABR1 or R2 expression that might correlate with seizure incidence. However, when administered daily for 6 days, 10 mg/kg MPEP or 0.5 mg/kg R-baclofen alone did not block seizures. A combination of 10 mg/kg MPEP and 0.5 mg/kg R-baclofen also reduced expression of GABABR2, although in this case the reduction was not statistically significant (88.8 ± 15.9%; p > 0.05). The combination treatment also did not produce significant changes in GABA<sub>B</sub>R1 or R2 subunit expression compared with vehicle-treated mice (Fig. 4, E and F; R1 expression 125.2 ± 24.6% of vehicle; R2 expression 107.0 ± 5.8% of vehicle; p > 0.05 for both).

**Acute and Subchronic Administration of the mGluR5-Positive Modulator CDPPB.** Based on our theory that audiogenic seizures result from an imbalance in group I mGluR and GABA<sub>B</sub> receptor signaling, we predicted that reducing GABA<sub>B</sub> receptor signaling might negate the anticonvulsant effect of MPEP. To test this, FMR1 mice were treated with 30 mg/kg MPEP and 60 mg/kg of the GABA<sub>B</sub> antagonist CGP46381 60 min before seizure testing (Fig. 5A). Treatment with CGP46381 alone exacerbated seizures in FMR1 mice (100% seizures with CGP46381; p = 0.039 versus vehicle), whereas the seizure incidence after treatment with MPEP plus CGP46381 was not significantly different from vehicle (27% seizure incidence; p = 0.15 compared with vehicle), indicating that CGP46381 reduced the effectiveness of MPEP in alleviating audiogenic seizures.

We also tested whether treatment with the mGluR5-positive allosteric modulator CDPPB could counteract the anticonvulsant effects of R-baclofen. It is noteworthy that treatment with 30 mg/kg CDPPB alone did not exacerbate seizure activity but instead completely blocked seizures (0% seizures with CDPPB; p = 0.002 versus vehicle; Fig. 5B). The seizure incidence after the combined treatment with 30 mg/kg CDPPB and 1 mg/kg R-baclofen (37%) was not different from vehicle (p = 0.29), indicating that the combination of a mGluR5-positive modulator plus GABA<sub>B</sub> agonist was less effective in preventing seizures than either drug administered alone.

A lower dose of CDPPB (10 mg/kg) administered alone had no effect on seizure incidence (45% seizure incidence; p = 0.44 compared with vehicle), whereas 10 mg/kg CDPPB administered with 1 mg/kg R-baclofen significantly reduced the incidence of seizures (0% compared with vehicle; p = 0.02; Fig. 5B).

We were intrigued by the finding that a high dose of the mGluR5-positive allosteric modulator CDPPB blocked seizures in FMR1 KO mice when administered acutely. To determine whether this effect persisted after repeated administrations, we treated FMR1 mice for 6 days with 30 mg/kg CDPPB and tested for seizures 1 h after the final dose. After subchronic treatment, 63% of the mice had seizures, which was not different from vehicle (83% seizure incidence; p = 0.58, Fig. 6A); this indicated that tolerance developed to the anticonvulsant effects of CDPPB after 6 days of administration. The levels of mGluR5 protein in the forebrains of mice 116.7 ± 30.7% of vehicle; R2 expression 94.0 ± 11.8% of vehicle; p > 0.05 for both).
injected subchronically with CDPPB was measured by quantitative Western blot (Fig. 6, B and C); there was a trend toward decreased mGluR5 expression in FMR1 mice (74.7 ± 4.8% of vehicle; p = 0.056). It is noteworthy that subchronic injection of vehicle or 30 mg/kg CDPPB did not induce seizures in wild-type mice (data not shown) and no changes in mGluR5 expression were detected in the forebrains of CDPPB-injected wild-type animals compared with vehicle controls (105.5 ± 9.0% of vehicle; p = 0.62; Fig. 6, B and C).

Subchronic Administration of Low-Dose R-Baclofen Modifies the Response of FMR1 Mice to a High Dose of MPEP. In a final series of experiments, mice were treated for 5 days (PND25–29) with low doses of MPEP (10 mg/kg) or R-baclofen (0.5 mg/kg), alone or in combination, followed by a single high dose of MPEP (30 mg/kg) 1 h before testing on PND30. In mice pretreated with only the low-dose MPEP, a single high dose of MPEP still blocked seizures (0% seizure incidence versus 88% in vehicle-treated mice; p = 0.005; Fig. 7).

Unexpectedly, in mice that were pretreated with a combination of low-dose MPEP and low-dose R-baclofen for 5 days a single injection of 30 mg/kg MPEP was no longer effective in preventing seizures (86% seizure incidence; p = 1.00 versus vehicle). Moreover, pretreatment for 5 days with low-dose R-baclofen alone also produced tolerance to the antiseizure effects of high-dose MPEP (57% seizure incidence; p = 0.28 versus vehicle). These results indicate that subchronic treatment with a low dose of R-baclofen can modulate the response to MPEP, suggesting cross-talk between the GABAβ and mGluR5 pathways.

Discussion

Our results show that when administered as single doses MPEP (30 mg/kg), R-baclofen (1 mg/kg), and the GABAβ-positive modulator GS-39783 (30 mg/kg) displayed robust suppression of audiogenic seizures in FMR1 mice. However, when FMR1 mice were treated daily for 6 days, MPEP re-
tained its anticonvulsant activity, whereas R-baclofen and GS-39783 did not. Baclofen has previously been shown to induce tolerance in several models of chronic pain (Lehmann et al., 2003; Sands et al., 2003) and in humans after intrathecal infusion (Akman et al., 1993; Nielsen et al., 2002). In the present study, Western blot analysis showed no significant difference in GABAB receptor expression in the forebrains of FMR1 mice after subchronic treatment with R-baclofen. This is consistent with previous findings suggesting that baclofen induces tolerance through mechanisms other than down-regulation of GABA<sub>B</sub> receptor expression (Lehmann et al., 2003; Sands et al., 2003). However, it is possible that microdissection and analysis of specific brain regions (e.g., the inferior colliculus, a brain region that may mediate audiogenic seizures) might have demonstrated regional changes in GABA<sub>B</sub> receptor expression after baclofen injection.

We initially hypothesized that targeting GABA<sub>B</sub> receptors with GS-39783, a positive allosteric modulator, rather than an orthosteric agonist (R-baclofen), might provide a better long-term approach given the overall theoretical advantages of using allosteric modulators as therapeutic drugs (Gregory et al., 2011; Keov et al., 2011) and the specific observations that GS-39783 has been shown to produce fewer side effects (Cryan et al., 2004) and less tolerance (Mombereau et al., 2004) after repeated administration in mouse models of anxiety. In addition, Gjoni and Urwyler (2008) demonstrated that prolonged administration of GS-39783 did not lead to GABAB<sub>R1</sub> receptor desensitization in cultured cells. However, in the present study, GS-39783 produced tolerance in FMR1 mice, with an accompanying decrease in GABAB<sub>R1</sub> receptor levels. The differences between our results examining the effects of GS-39783 on seizures in FMR1 mice and those of Mombereau et al., (2004) who studied the effects of this drug in tests of anxiety and depression in GABAB<sub>R1</sub> null mice may be caused by differences in the strain of mice used (C57/BL6 versus BALB/c), route of administration (intraperitoneal versus oral), length of treatment time (6 versus 21
and the doses used (30 mg/kg in the present study versus 0.3–30 mg/kg in Mombereau et al.). In our experiments, doses of GS-39783 below 30 mg/kg were tested but seemed to have minimal efficacy in blocking seizures.

Based on the efficacy of both mGluR antagonists and GABAB agonists in reducing audiogenic seizures after single administrations, we hypothesized that a combination of low doses of MPEP and \( R \)-baclofen might prevent seizures while also avoiding the adverse side effects and tolerance seen with higher doses of baclofen. When administered acutely, a combination of MPEP and \( R \)-baclofen prevented seizures; however, the effect was lost after repeated administration. A possible explanation for this finding is that, when administered acutely, baclofen might preferentially target presynaptic GABA\(_R\) receptors to reduce glutamate release thus reducing mGluR5 stimulation and relieving audiogenic seizures. However, after repeated administrations, GABA\(_R\) desensitization occurs (which may or may not be accompanied by changes in receptor expression) and glutamate release is no longer blocked, thus restoring enhanced mGluR5 signaling and seizures in FMR1 mice. When low doses of MPEP and \( R \)-baclofen are combined, the additive effect of reduced glutamate release and decreased mGluR5 activation is responsible for alleviating seizures. We hypothesize that tolerance occurs after repeated administration caused by the loss of the GABA\(_R\)-mediated reduction in glutamate release, because the receptor blockade induced by the low dose of MPEP alone is not sufficient to prevent seizures. Further experiments are needed to examine this hypothesis.

Our data also demonstrate that \( R \)-baclofen promotes tolerance to the anticonvulsant effects of MPEP in FMR1 mice. High-dose MPEP on day 6 of treatment retained anticonvul-

Fig. 5. A, the GABAA antagonist CGP46381 dramatically increased seizure incidence in FMR1 knockout mice and seizure incidence after treatment with CGP46381 plus MPEP was not different from vehicle, indicating that CGP46381 partially blocked the anticonvulsant effect of MPEP. B, treatment with a high dose (30 mg/kg) of the mGluR5-positive allosteric modulator CDPPB completely blocked seizures, whereas a lower dose (10 mg/kg) had no effect on seizure incidence in FMR1 mice. Treatment with 10 mg/kg CDPPB plus 1 mg/kg \( R \)-baclofen blocked seizures, whereas treatment with 30 mg/kg CDPPB plus 1 mg/kg \( R \)-baclofen produced no significant difference in seizure incidence compared with vehicle; this indicates that a high dose of CDPPB partially blocked the anticonvulsant effects of \( R \)-baclofen in FMR1 mice.

Fig. 6. The effects of subchronic administration of the mGluR5-positive allosteric modulator CDPPB on seizures and expression of mGluR5. A, subchronic treatment for 6 days (PND25–30) with 30 mg/kg CDPPB did not block audiogenic seizures in FMR1 knockout mice (\( p > 0.58 \)). B, after subchronic treatment with CDPPB expression of mGluR5 was decreased (\( p = 0.055 \)) in FMR1 knockout but not wild-type (WT; \( p = 0.62 \)) mice. C, representative Western blots of mGluR5 expression and the GAPDH loading control in the forebrains of wild-type (top) and FMR1 (bottom) mice.
sant efficacy in mice that had been pretreated for 5 days with low-dose MPEP. However, tolerance ensued when low-dose MPEP was administered together with low-dose R-baclofen over the same 5-day period. Even more surprising was that pretreatment of the mice with low-dose R-baclofen alone for 5 days also induced tolerance to the antiseizure effects of MPEP given on day 6. Similar to the hypothesis above, if R-baclofen-induced GABA<sub>B</sub> receptor desensitization occurred at the high drug concentration, thereby effectively decreasing mGluR5 signaling and reducing audiogenic seizure susceptibility. However, this is unlikely given that tolerance to the antiseizure effects of high-dose CDPPB developed after subchronic administration despite a reduction in mGluR5 expression (Fig. 6). Another possibility is that the pharmacological actions of CDPPB may convert from a positive modulator at low concentrations to a negative allosteric modulator at high concentrations. CDPPB has been shown to potentiate glutamate stimulation of mGluR5 at very low concentrations with an EC<sub>50</sub> of 27 nM (Kinney et al., 2005). Moreover, CDPPB binds to the same site as MPEP in the transmembrane region of mGluR5 (Chen et al., 2007; Rodriguez et al., 2010). We obtained support for this idea by examining the effects of CDPPB on mGluR5 expressed in human embryonic kidney 293 cells. We observed that 10 µM CDPPB blocked glutamate responses in mGluR5 expressing cells, and at 200 nM it reduced the glutamate response (Supplemental Fig. 1). The 200 nM concentration may be pharmacologically relevant because Parmentier-Batteur et al. (2010) have shown that in rats injected with 30 mg/kg CDPPB brain levels of CDPPB were in the range of 400 to 800 nM. We speculate that subtle differences in the precise docking orientation within the pocket of some (but perhaps not all) allosteric modulators at this site may have concentration-dependent effects such that positive versus negative allosteric receptor modulation for some modulators may depend on drug concentration. Together, these findings may have implications for mGluR drug development beyond the treatment of FXS in that positive allosteric modulators of mGluR5 are being developed for use as novel antipsychotics (Gasparini et al., 2008; Uslaner et al., 2009; Rodriguez et al., 2010).

There is presently no cure for FXS, and current therapies are aimed at treating specific symptoms such as anxiety and hyperactivity. Recent advances in understanding the pathobiology of FXS have led to new and exciting drug targets with the potential to treat the disease itself rather than individual symptoms (see Levenga et al., 2010 and Hampson et al., 2011 for reviews). Based on these findings, clinical trials are underway examining the use of several mGluR5-negative modulators and the GABA<sub>B</sub> agonist arbaclofen in treating FXS (www.clinicaltrials.gov). Taken together, the results of our study indicate that in FMR1 mice tolerance develops rapidly to the anticonvulsant effects of R-baclofen, even at very low concentrations.


Coven MS, Djouma E, and Lawrence AD (2005) The metabotropic glutamate 5 receptor antagonist 3-[2-(methyl-1,3-thiazol-4-yl)ethynyl]-pyridine reduces ethanol self-administration in multiple strains of alcohol-prefering rats and regulates olfactory glutamatergic systems. J Pharmacol Exp Ther 315:590–600.


Uslaner JM, Parmentier-Batteur S, Fick RB, Surles NO, Lam JS, McNaughton CH, Jacobson MA, and Hutsen PH (2009) Dose-dependent effect of CDPPB, the mGluR5 positive allosteric modulator, on recognition memory is associated with GluB1 and CREB phosphorylation in the prefrontal cortex and hippocampus. Neuropharmacology 57:531–539.

